Prostate cancer statistics, 2025

Abstract

Prostate cancer is the most common cancer among men in the United States, and the incidence of advanced disease is increasing rapidly. This article provides an overview of prostate cancer occurrence using population-based incidence and mortality data from the National Cancer Institute and the Centers for Disease Control and Prevention. Prostate cancer incidence trends have reversed from a decline of 6.4% per year during 2007 through 2014 to an increase of 3.0% annually during 2014 through 2021. The increasing trend is confined to distant-stage disease in men younger than 55 years and to regional/distant-stage disease in men aged 55-69 years but includes early stage disease in men aged 70 years and older. Over the past decade of data, distant-stage disease has increased by 2.6% annually in men younger than 55 years, 6.0% annually in men aged 55-69 years, and 6.2% annually in men aged 70 years and older. American Indian/Alaska Native, Asian American/Pacific Islander, and Hispanic men are less likely than Black and White men to be diagnosed with localized disease (64%-67% vs. 71%-72%). Compared with White men, American Indian/Alaska Native men have 12% higher prostate cancer mortality despite 13% lower incidence, whereas Black men have double the prostate cancer mortality, with 67% higher incidence. In summary, continued increases in the diagnosis of advanced prostate cancer and persistent racial disparities underscore the need for redoubled efforts to optimize early detection while limiting overdiagnosis and to understand and address barriers to equitable outcomes.

Keywords: cancer screening; cancer statistics; cancer surveillance; prostate cancer; stage at diagnosis.

FIGURE 1

Prostate cancer incidence and mortality rates by race and ethnicity, United States. All rates are age‐adjusted to the 2000 US standard population. Incidence rates are adjusted for delays in case reporting. For AIAN individuals, incidence rates are limited to Purchased/Referred Care Delivery Area counties, and mortality rates (entire United States) are adjusted for misclassification on death certificates. Racial groups are exclusive of Hispanic ethnicity. AAPI indicates Asian American and Pacific Islander; AIAN, American Indian and Alaska Native. Source: Incidence, North American Association of Central Cancer Registries, 2024; mortality, National Center for Health Statistics, 2025.

FIGURE 2

Trends in prostate cancer incidence and mortality by race, United States. Rates are age‐adjusted to the 2000 US standard population. Incidence rates are adjusted for delays in case reporting, and 2020 incidence data are separated from the trendline because of the coronavirus disease 2019 pandemic. For AIAN individuals, incidence data are restricted to Purchased/Referred Care Delivery Area counties, and mortality data (entire United States) are adjusted for misclassification on death certificates. AAPI indicates Asian American and Pacific Islander; AIAN, American Indian and Alaska Native. Source: Incidence, North American Association of Central Cancer Registries, 2024; mortality, National Center for Health Statistics, 2025.

FIGURE 3

Five‐year relative survival for prostate cancer by stage and race, 2015–2021. Based on cases diagnosed during 2015–2021, followed through 2022. Racial groups are exclusive of Hispanic ethnicity. AAPI indicates Asian American and Pacific Islander; AIAN, American Indian and Alaska Native. Source: Surveillance, Epidemiology, and End Results 21, 2025.

FIGURE 4

Stage distribution for prostate cancer by race and ethnicity, 2017–2021. Racial groups are exclusive of Hispanic ethnicity. Stage categories may not sum to 100% because of rounding. AAPI indicates Asian American and Pacific Islander; AIAN, American Indian and Alaska Native. Source: North American Association of Central Cancer Registries, 2024.

FIGURE 5

Prostate cancer mortality by race and age, United States, 2019–2023. All rates are age‐adjusted to the 2000 US standard population. For rate values by 5‐year age group from 40–44 to 85+, see Table S1. Racial groups are exclusive of Hispanic ethnicity. AAPI indicates Asian American and Pacific Islander; AIAN, American Indian and Alaska Native. Source: National Center for Health Statistics, 2025.

FIGURE 6

Trends in prostate‐specific antigen testing within the last year by age and race, 2005–2023. Estimates are age‐adjusted to the year 2000 US population standard using three age groups: 40–54, 55–69, and ≥70 years. The National Health Interview Survey underwent a significant redesign in 2019, preventing comparability to prior years. Prostate cancer screening is defined among males who have not been diagnosed with prostate cancer. Estimates were unstable for American Indian and Alaska Native individuals for most data years and thus are not shown. Source: National Health Interview Surveys, 2005–2023.